Search:
Wednesday, Feb-19 2020 19:47 WIB
  • AGRI 1,299.800 3.900 (0.301%)
  • BASIC-IND 884.690 9.590 (1.096%)
  • BISNIS-27 535.520 4.760 (0.897%)
  • COMPOSITE 5,928.790 41.830 (0.711%)
  • CONSUMER 1,922.010 13.980 (0.733%)
  • DBX 1,032.110 8.240 (0.805%)
  • FINANCE 1,345.850 10.610 (0.795%)
  • I-GRADE 173.160 1.460 (0.850%)
  • IDX30 526.610 4.760 (0.912%)
  • IDX80 135.030 1.110 (0.829%)
  • IDXBUMN20 372.400 2.770 (0.749%)
  • IDXG30 138.260 1.020 (0.743%)
  • IDXHIDIV20 479.950 4.060 (0.853%)
  • IDXSMC-COM 236.460 1.290 (0.549%)
  • IDXSMC-LIQ 285.410 0.750 (0.263%)
  • IDXV30 128.020 0.520 (0.408%)
  • INFOBANK15 1,033.160 8.710 (0.850%)
  • INFRASTRUC 1,018.420 4.630 (0.457%)
  • Investor33 450.010 3.970 (0.890%)
  • ISSI 171.050 1.150 (0.677%)
  • JII 629.410 5.440 (0.872%)
  • JII70 211.210 1.640 (0.783%)
  • KOMPAS100 1,206.580 9.140 (0.763%)
  • LQ45 964.390 8.110 (0.848%)
  • MANUFACTUR 1,343.420 13.790 (1.037%)
  • MBX 1,659.950 11.500 (0.698%)
  • MINING 1,431.690 6.920 (0.486%)
  • MISC-IND 1,099.460 20.830 (1.931%)
  • MNC36 335.940 2.640 (0.792%)
  • PEFINDO25 306.670 -0.130 (-0.042%)
  • PROPERTY 458.540 -0.300 (-0.065%)
  • SMinfra18 296.850 2.550 (0.866%)
  • SRI-KEHATI 384.410 3.560 (0.935%)
  • TOTAL_MARKET 5,928.790 41.830 (0.711%)
  • TRADE 704.850 1.910 (0.272%)
  • © 2010 IMQ - LKBN ANTARA
  • AALI 11,200 100 (0.90%)
  • ABBA 65 -1 (-1.52%)
  • ACES 1,560 -30 (-1.89%)
  • ACST 690 -5 (-0.72%)
  • ADES 910 0 (0.00%)
  • ADHI 995 25 (2.58%)
  • ADMF 10,000 0 (0.00%)
  • ADMG 134 0 (0.00%)
  • ADRO 1,305 -25 (-1.88%)
  • AGAR 464 30 (6.91%)
  • AGII 550 -20 (-3.51%)
  • AGRO 145 1 (0.69%)
  • AGRS 150 -2 (-1.32%)
  • AHAP 53 1 (1.92%)
  • AKKU 50 0 (0.00%)
  • AKPI 350 -50 (-12.50%)
  • AKRA 3,040 -60 (-1.94%)
  • AKSI 376 8 (2.17%)
  • ALKA 330 18 (5.77%)
  • ALMI 292 22 (8.15%)
  • ALTO 398 -2 (-0.50%)
  • AMAR 306 2 (0.66%)
  • AMFG 3,210 -90 (-2.73%)
  • AMOR 2,330 10 (0.43%)
  • AMRT 810 25 (3.18%) © 2010 IMQ - LKBN ANTARA
  • ANDI 50 0 (0.00%)
  • ANTM 705 15 (2.17%)
  • APEX 200 0 (0.00%)
  • APIC 700 50 (7.69%)
  • APLI 160 16 (11.11%)
  • APLN 158 2 (1.28%)
  • ARKA 1,950 30 (1.56%)
  • ARNA 448 -6 (-1.32%)
  • ARTO 3,650 70 (1.96%)
  • ASGR 940 5 (0.53%)
  • ASII 6,250 150 (2.46%)
  • ASJT 120 0 (0.00%)
  • ASMI 1,300 0 (0.00%)
  • ASPI 300 60 (25.00%)
  • ASPI-W 158 96 (154.84%)
  • ASRI 180 3 (1.69%)
  • ASRM 2,050 60 (3.02%)
  • ASSA 555 0 (0.00%)
  • AUTO 1,170 -15 (-1.27%)
  • AYLS 204 -68 (-25.00%)
  • AYLS-W 17 -2 (-10.53%)
  • BABP 50 0 (0.00%)
  • BABP-W3 35 -1 (-2.78%)
  • BABP-W4 10 -1 (-9.09%)
  • BACA 344 64 (22.86%) © 2010 IMQ - LKBN ANTARA
  • BAJA 65 0 (0.00%)
  • BAPA 51 0 (0.00%)
  • BAPI 50 0 (0.00%)
  • BAPI-W 5 1 (25.00%)
  • BATA 610 0 (0.00%)
  • BBCA 33,475 0 (0.00%)
  • BBHI 110 0 (0.00%)
  • BBKP 216 12 (5.88%)
  • BBLD 428 0 (0.00%)
  • BBNI 7,775 75 (0.97%)
  • BBRI 4,480 80 (1.82%)
  • BBRM 50 0 (0.00%)
  • BBTN 1,895 0 (0.00%)
  • BCAP 148 -1 (-0.67%)
  • BCIP 50 0 (0.00%)
  • BDMN 3,590 40 (1.13%)
  • BEEF 364 2 (0.55%)
  • BEEF-W 42 0 (0.00%)
  • BEKS 50 0 (0.00%)
  • BELL 620 30 (5.08%)
  • BEST 170 1 (0.59%)
  • BFIN 500 0 (0.00%)
  • BGTG 52 0 (0.00%)
  • BHIT 64 0 (0.00%)
  • BIKA 195 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • BIMA 50 0 (0.00%)
  • BINA 880 -35 (-3.83%)
  • BIPI 50 0 (0.00%)
  • BIPI-W 9 1 (12.50%)
  • BIRD 2,390 -40 (-1.65%)
  • BISI 980 0 (0.00%)
  • BJBR 1,020 -10 (-0.97%)
  • BJTM 640 5 (0.79%)
  • BKDP 51 -4 (-7.27%)
  • BKSL 53 -1 (-1.85%)
  • BKSL-W 11 0 (0.00%)
  • BKSW 158 -7 (-4.24%)
  • BLTA 50 0 (0.00%)
  • BLUE 530 -5 (-0.93%)
  • BMRI 7,950 125 (1.60%)
  • BMSR 82 4 (5.13%)
  • BMTR 350 4 (1.16%)
  • BNBA 316 -2 (-0.63%)
  • BNBR 50 0 (0.00%)
  • BNGA 870 30 (3.57%)
  • BNII 196 2 (1.03%)
  • BNLI 1,215 0 (0.00%)
  • BOGA 1,580 0 (0.00%)
  • BOLA 234 -2 (-0.85%)
  • BOLT 835 15 (1.83%) © 2010 IMQ - LKBN ANTARA
  • BOSS 112 7 (6.67%)
  • BRIS 304 0 (0.00%)
  • BRMS 50 0 (0.00%)
  • BRPT 1,235 15 (1.23%)
  • BRPT-W 880 0 (0.00%)
  • BSDE 1,155 0 (0.00%)
  • BSIM-W3 26 -3 (-10.34%)
  • BTON 202 3 (1.51%)
  • BTPN 2,960 40 (1.37%)
  • BTPS 4,300 -70 (-1.60%)
  • BUDI 99 1 (1.02%)
  • BULL 162 0 (0.00%)
  • BULL-W2 19 -1 (-5.00%)
  • BUMI 51 -1 (-1.92%)
  • BUVA 83 -2 (-2.35%)
  • BVIC 65 1 (1.56%)
  • BWPT 115 4 (3.60%)
  • CAKK 52 1 (1.96%)
  • CAKK-W 18 0 (0.00%)
  • CAMP 294 -4 (-1.34%)
  • CANI 168 10 (6.33%)
  • CARS 81 -2 (-2.41%)
  • CASA 414 0 (0.00%)
  • CCSI 248 -2 (-0.80%)
  • CEKA 1,570 -10 (-0.63%) © 2010 IMQ - LKBN ANTARA
  • CENT 72 -1 (-1.37%)
  • CFIN 248 0 (0.00%)
  • CINT 274 -2 (-0.72%)
  • CITA 1,900 -100 (-5.00%)
  • CITY 58 1 (1.75%)
  • CITY-W 19 -1 (-5.00%)
  • CLAY 2,820 100 (3.68%)
  • CLEO 480 -6 (-1.23%)
  • CLPI 735 -5 (-0.68%)
  • CMNP 1,750 -50 (-2.78%)
  • CNKO 50 0 (0.00%)
  • CNTX 342 22 (6.88%)
  • COCO 930 95 (11.38%)
  • COWL 50 0 (0.00%)
  • CPIN 6,800 125 (1.87%)
  • CPRI 50 0 (0.00%)
  • CPRI-W 19 -1 (-5.00%)
  • CPRO 50 0 (0.00%)
  • CSAP 440 4 (0.92%)
  • CSIS 71 1 (1.43%)
  • CSRA 600 -30 (-4.76%)
  • CTRA 975 -5 (-0.51%)
  • CTTH 51 -1 (-1.92%)
  • DADA 164 6 (3.80%)
  • DADA-W 14 4 (40.00%) © 2010 IMQ - LKBN ANTARA
  • DART 254 -32 (-11.19%)
  • DAYA 284 0 (0.00%)
  • DEAL 118 8 (7.27%)
  • DEFI 1,795 0 (0.00%)
  • DEWA 50 0 (0.00%)
  • DFAM 386 -4 (-1.03%)
  • DGIK 50 0 (0.00%)
  • DILD 280 -2 (-0.71%)
  • DIVA 2,210 -190 (-7.92%)
  • DKFT 114 0 (0.00%)
  • DMAS 286 8 (2.88%)
  • DMMX 180 0 (0.00%)
  • DMND 950 0 (0.00%)
  • DNAR 208 -2 (-0.95%)
  • DNET 3,200 10 (0.31%)
  • DOID 218 0 (0.00%)
  • DSFI 98 0 (0.00%)
  • DSNG 448 16 (3.70%)
  • DSSA 17,875 2,375 (15.32%)
  • DUCK 1,200 0 (0.00%)
  • DVLA 2,200 30 (1.38%)
  • DWGL 284 28 (10.94%)
  • DWGL-W 85 15 (21.43%)
  • DYAN 64 3 (4.92%)
  • EAST 87 -1 (-1.14%) © 2010 IMQ - LKBN ANTARA
  • EAST-W 13 1 (8.33%)
  • EKAD 1,045 5 (0.48%)
  • ELSA 262 6 (2.34%)
  • ELTY 50 0 (0.00%)
  • EMDE 200 0 (0.00%)
  • EMTK 5,500 0 (0.00%)
  • ENRG 50 0 (0.00%)
  • ERAA 1,810 0 (0.00%)
  • ERTX 110 -37 (-25.17%)
  • ESIP 158 4 (2.60%)
  • ESIP-W 16 1 (6.67%)
  • ESSA 234 0 (0.00%)
  • ESTI 50 0 (0.00%)
  • ETWA 55 -3 (-5.17%)
  • EXCL 2,760 40 (1.47%)
  • FAST 1,175 5 (0.43%)
  • FILM 200 -4 (-1.96%)
  • FIRE 139 7 (5.30%)
  • FITT 72 2 (2.86%)
  • FITT-W 54 9 (20.00%)
  • FOOD 94 1 (1.08%)
  • FORU 105 24 (29.63%)
  • FORZ 50 0 (0.00%)
  • FPNI 80 0 (0.00%)
  • FREN 108 1 (0.93%) © 2010 IMQ - LKBN ANTARA
  • FREN-W 71 2 (2.90%)
  • FUJI 105 2 (1.94%)
  • GAMA 50 0 (0.00%)
  • GDST 71 -2 (-2.74%)
  • GEMA 364 -6 (-1.62%)
  • GGRM 55,200 175 (0.32%)
  • GGRP 462 12 (2.67%)
  • GHON 1,680 280 (20.00%)
  • GIAA 342 2 (0.59%)
  • GJTL 484 10 (2.11%)
  • GLOB 358 18 (5.29%)
  • GLVA 268 28 (11.67%)
  • GMFI 97 0 (0.00%)
  • GMTD 18,975 -25 (-0.13%)
  • GOLD 220 0 (0.00%)
  • GOOD 1,330 15 (1.14%)
  • GPRA 55 -4 (-6.78%)
  • GTBO 100 -24 (-19.35%)
  • GWSA 143 -1 (-0.69%)
  • HDFA 149 0 (0.00%)
  • HDIT 570 -5 (-0.87%)
  • HEAL 3,340 30 (0.91%)
  • HELI 171 -1 (-0.58%)
  • HELI-W 12 0 (0.00%)
  • HERO 960 70 (7.87%) © 2010 IMQ - LKBN ANTARA
  • HEXA 3,190 -10 (-0.31%)
  • HITS 570 -5 (-0.87%)
  • HKMU 141 -5 (-3.42%)
  • HMSP 1,955 -5 (-0.26%)
  • HOKI 995 20 (2.05%)
  • HOKI-W 620 0 (0.00%)
  • HOTL 97 -4 (-3.96%)
  • HRME 940 -5 (-0.53%)
  • HRTA 252 0 (0.00%)
  • HRUM 1,230 25 (2.07%)
  • IBFN 388 -10 (-2.51%)
  • IBFN-W 16 2 (14.29%)
  • ICBP 11,000 150 (1.38%)
  • ICON 74 -2 (-2.63%)
  • IFII 163 -6 (-3.55%)
  • IFSH 470 24 (5.38%)
  • IGAR 290 -2 (-0.68%)
  • IKAI 50 0 (0.00%)
  • IKAN 210 -14 (-6.25%)
  • IMAS 860 15 (1.78%)
  • IMJS 248 0 (0.00%)
  • IMPC 1,100 0 (0.00%)
  • INAF 715 65 (10.00%)
  • INAI 398 12 (3.11%)
  • INCF 50 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • INCI 384 0 (0.00%)
  • INCO 3,040 -50 (-1.62%)
  • INDF 7,050 -50 (-0.70%)
  • INDO 130 33 (34.02%)
  • INDO-W 50 25 (100.00%)
  • INDR 2,150 10 (0.47%)
  • INDS 1,940 -50 (-2.51%)
  • INDX 51 1 (2.00%)
  • INDY 860 10 (1.18%)
  • INKP 6,700 150 (2.29%)
  • INOV 304 -6 (-1.94%)
  • INPC 51 0 (0.00%)
  • INPC-W 5 -1 (-16.67%)
  • INPP 820 0 (0.00%)
  • INPS 3,910 0 (0.00%)
  • INTD 200 -40 (-16.67%)
  • INTP 17,325 75 (0.43%)
  • IPCC 550 0 (0.00%)
  • IPCM 165 0 (0.00%)
  • IPOL 70 -9 (-11.39%)
  • IPTV 386 0 (0.00%)
  • IPTV-W 95 5 (5.56%)
  • IRRA 750 5 (0.67%)
  • ISAT 2,300 130 (5.99%)
  • ISSP 170 -1 (-0.58%) © 2010 IMQ - LKBN ANTARA
  • ITIC 2,080 -120 (-5.45%)
  • ITMA 424 -8 (-1.85%)
  • ITMA-W 54 4 (8.00%)
  • ITMG 10,800 -150 (-1.37%)
  • JAST 1,460 0 (0.00%)
  • JAYA 77 -1 (-1.28%)
  • JAYA-W 17 0 (0.00%)
  • JKON 490 12 (2.51%)
  • JMAS 650 -170 (-20.73%)
  • JPFA 1,560 5 (0.32%)
  • JRPT 492 0 (0.00%)
  • JSKY 106 -6 (-5.36%)
  • JSMR 5,000 90 (1.83%)
  • JTPE 985 -5 (-0.51%)
  • KAEF 845 70 (9.03%)
  • KARW 50 0 (0.00%)
  • KAYU 63 -2 (-3.08%)
  • KBLI 466 4 (0.87%)
  • KDSI 1,090 -10 (-0.91%)
  • KEEN 396 18 (4.76%)
  • KEJU 820 5 (0.61%)
  • KIAS 52 1 (1.96%)
  • KICI 228 -6 (-2.56%)
  • KIJA 294 2 (0.68%)
  • KINO 3,120 -10 (-0.32%) © 2010 IMQ - LKBN ANTARA
  • KIOS 256 4 (1.59%)
  • KJEN 1,995 0 (0.00%)
  • KKGI 218 6 (2.83%)
  • KLBF 1,435 40 (2.87%)
  • KMTR 270 0 (0.00%)
  • KOBX 108 1 (0.93%)
  • KOIN 135 0 (0.00%)
  • KOPI 610 -5 (-0.81%)
  • KOTA 700 0 (0.00%)
  • KOTA-W 450 28 (6.64%)
  • KPAL 153 -2 (-1.29%)
  • KPAS 52 1 (1.96%)
  • KPAS-W 21 -4 (-16.00%)
  • KPIG 124 1 (0.81%)
  • KRAS 272 2 (0.74%)
  • KREN 466 -2 (-0.43%)
  • LAND 925 -5 (-0.54%)
  • LEAD 50 0 (0.00%)
  • LIFE 6,150 300 (5.13%)
  • LINK 3,590 -10 (-0.28%)
  • LION 490 80 (19.51%)
  • LMAS 93 1 (1.09%)
  • LPCK 820 -15 (-1.80%)
  • LPIN 212 2 (0.95%)
  • LPKR 236 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • LPLI 67 -1 (-1.47%)
  • LPPF 3,550 50 (1.43%)
  • LPPS 77 -1 (-1.28%)
  • LRNA 161 -9 (-5.29%)
  • LSIP 1,160 -5 (-0.43%)
  • LTLS 600 0 (0.00%)
  • LUCK 436 2 (0.46%)
  • MAIN 875 10 (1.16%)
  • MAMI 50 0 (0.00%)
  • MAMI-W 12 -1 (-7.69%)
  • MAPA 4,000 100 (2.56%)
  • MAPB 1,550 0 (0.00%)
  • MAPI 875 -10 (-1.13%)
  • MARI 160 -7 (-4.19%)
  • MARK 478 -4 (-0.83%)
  • MASA 480 -12 (-2.44%)
  • MBAP 1,975 85 (4.50%)
  • MBSS 426 4 (0.95%)
  • MBTO 81 -4 (-4.71%)
  • MCAS 1,755 0 (0.00%)
  • MCOR 105 1 (0.96%)
  • MDIA 50 0 (0.00%)
  • MDKA 1,260 15 (1.20%)
  • MDKI 180 -8 (-4.26%)
  • MDLN 183 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • MEDC 705 5 (0.71%)
  • MEDC-W 150 9 (6.38%)
  • MEGA 5,600 -50 (-0.88%)
  • MERK 2,210 0 (0.00%)
  • META 149 -3 (-1.97%)
  • MFIN 1,280 0 (0.00%)
  • MFMI 406 -4 (-0.98%)
  • MGRO 815 5 (0.62%)
  • MICE 356 10 (2.89%)
  • MIKA 2,590 -10 (-0.38%)
  • MINA 50 -21 (-29.58%)
  • MKNT 50 0 (0.00%)
  • MLBI 15,200 0 (0.00%)
  • MLIA 600 -5 (-0.83%)
  • MLPL 67 2 (3.08%)
  • MLPT 388 52 (15.48%)
  • MMLP 167 3 (1.83%)
  • MNCN 1,490 -5 (-0.33%)
  • MOLI 1,035 0 (0.00%)
  • MPMX 630 10 (1.61%)
  • MPOW 71 2 (2.90%)
  • MPPA 115 1 (0.88%)
  • MRAT 138 3 (2.22%)
  • MREI 5,900 675 (12.92%)
  • MSIN 392 -10 (-2.49%) © 2010 IMQ - LKBN ANTARA
  • MSKY 1,290 -5 (-0.39%)
  • MTDL 1,735 -5 (-0.29%)
  • MTLA 496 -19 (-3.69%)
  • MTSM 156 -50 (-24.27%)
  • MTWI 61 2 (3.39%)
  • MYOH 1,165 5 (0.43%)
  • MYOR 2,040 10 (0.49%)
  • MYTX 54 -1 (-1.82%)
  • NATO 1,140 0 (0.00%)
  • NELY 131 1 (0.77%)
  • NFCX 2,890 -20 (-0.69%)
  • NICK 302 -2 (-0.66%)
  • NIKL 490 16 (3.38%)
  • NIRO 147 -1 (-0.68%)
  • NRCA 350 4 (1.16%)
  • NUSA 50 0 (0.00%)
  • NUSA-W 4 0 (0.00%)
  • NZIA 454 0 (0.00%)
  • NZIA-W 65 1 (1.56%)
  • OASA 380 10 (2.70%)
  • OCAP 114 -2 (-1.72%)
  • OKAS 102 11 (12.09%)
  • OPMS 76 0 (0.00%)
  • PADI 50 0 (0.00%)
  • PALM 192 -10 (-4.95%) © 2010 IMQ - LKBN ANTARA
  • PAMG 159 5 (3.25%)
  • PANI 90 10 (12.50%)
  • PANR 250 -2 (-0.79%)
  • PANS 1,230 -15 (-1.20%)
  • PBID 935 0 (0.00%)
  • PBRX 440 12 (2.80%)
  • PBSA 760 60 (8.57%)
  • PCAR 238 -8 (-3.25%)
  • PEGE 145 0 (0.00%)
  • PEHA 940 -10 (-1.05%)
  • PGAS 1,530 25 (1.66%)
  • PGJO 95 -1 (-1.04%)
  • PICO 820 15 (1.86%)
  • PJAA 860 0 (0.00%)
  • PLIN 3,200 0 (0.00%)
  • PMJS 126 1 (0.80%)
  • PNBN 1,220 20 (1.67%)
  • PNIN 1,010 0 (0.00%)
  • PNLF 276 0 (0.00%)
  • POLA 53 1 (1.92%)
  • POLI 1,105 -140 (-11.24%)
  • POLL 11,650 0 (0.00%)
  • POLY 50 -1 (-1.96%)
  • POOL 50 0 (0.00%)
  • POSA 50 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • POSA-W 4 0 (0.00%)
  • POWR 800 -5 (-0.62%)
  • PPRE 206 0 (0.00%)
  • PPRO 53 0 (0.00%)
  • PRAS 140 16 (12.90%)
  • PRDA 3,740 -60 (-1.58%)
  • PRIM-W 27 -2 (-6.90%)
  • PSAB 242 14 (6.14%)
  • PSDN 148 -11 (-6.92%)
  • PSKT 50 0 (0.00%)
  • PSSI 168 1 (0.60%)
  • PTBA 2,400 20 (0.84%)
  • PTPP 1,495 10 (0.67%)
  • PTPW 880 0 (0.00%)
  • PTRO 1,500 0 (0.00%)
  • PTSN 234 -2 (-0.85%)
  • PURA 206 2 (0.98%)
  • PURA-W 19 -1 (-5.00%)
  • PURE 128 2 (1.59%)
  • PURE-W 29 2 (7.41%)
  • PWON 595 -5 (-0.83%)
  • PYFA 185 5 (2.78%)
  • PZZA 1,000 -15 (-1.48%)
  • R-LQ45X 1,000 -3 (-0.30%)
  • RAJA 128 3 (2.40%) © 2010 IMQ - LKBN ANTARA
  • RALS 1,000 5 (0.50%)
  • RANC 300 0 (0.00%)
  • RBMS 53 -1 (-1.85%)
  • RDTX 5,200 150 (2.97%)
  • REAL 112 -8 (-6.67%)
  • REAL-W 13 0 (0.00%)
  • RELI 185 0 (0.00%)
  • RIGS 300 2 (0.67%)
  • RISE 462 -14 (-2.94%)
  • RODA 59 6 (11.32%)
  • ROTI 1,300 0 (0.00%)
  • RUIS 224 4 (1.82%)
  • SAFE 193 3 (1.58%)
  • SAME 192 -2 (-1.03%)
  • SATU 57 1 (1.79%)
  • SCCO 9,125 0 (0.00%)
  • SCMA 1,360 -25 (-1.81%)
  • SDMU 50 0 (0.00%)
  • SDPC 89 -1 (-1.11%)
  • SFAN 890 -5 (-0.56%)
  • SFAN-W 402 92 (29.68%)
  • SHIP 745 0 (0.00%)
  • SIDO 1,280 20 (1.59%)
  • SILO 6,850 -25 (-0.36%)
  • SIMP 352 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • SINI 1,210 15 (1.26%)
  • SINI-W 450 -70 (-13.46%)
  • SIPD 1,000 175 (21.21%)
  • SKRN 500 0 (0.00%)
  • SLIS 4,770 40 (0.85%)
  • SMAR 3,600 -50 (-1.37%)
  • SMBR 316 -2 (-0.63%)
  • SMCB 1,000 30 (3.09%)
  • SMDM 102 -3 (-2.86%)
  • SMDR 199 -1 (-0.50%)
  • SMGR 11,750 -25 (-0.21%)
  • SMKL 202 -12 (-5.61%)
  • SMKL-W 21 0 (0.00%)
  • SMMT 111 0 (0.00%)
  • SMRA 905 -25 (-2.69%)
  • SMSM 1,470 10 (0.68%)
  • SOCI 136 5 (3.82%)
  • SONA 4,900 -375 (-7.11%)
  • SOSS 384 -4 (-1.03%)
  • SOSS-W 46 -19 (-29.23%)
  • SOTS 228 0 (0.00%)
  • SOTS-W 59 1 (1.72%)
  • SPMA 304 -2 (-0.65%)
  • SPTO 830 5 (0.61%)
  • SQMI 238 47 (24.61%) © 2010 IMQ - LKBN ANTARA
  • SRAJ 220 -10 (-4.35%)
  • SRIL 230 4 (1.77%)
  • SRSN 62 -1 (-1.59%)
  • SRTG 3,600 10 (0.28%)
  • SSIA 680 10 (1.49%)
  • SSMS 800 5 (0.63%)
  • STAR 155 -2 (-1.27%)
  • STTP 7,700 700 (10.00%)
  • SULI 50 -1 (-1.96%)
  • SWAT 88 0 (0.00%)
  • TAMA 420 -54 (-11.39%)
  • TAMA-W 17 0 (0.00%)
  • TAMU 164 -1 (-0.61%)
  • TAXI 50 0 (0.00%)
  • TBIG 1,190 -15 (-1.24%)
  • TBLA 745 -10 (-1.32%)
  • TBMS 830 0 (0.00%)
  • TCID 9,800 0 (0.00%)
  • TCPI 7,200 225 (3.23%)
  • TDPM 196 -6 (-2.97%)
  • TEBE 1,800 5 (0.28%)
  • TELE 179 -18 (-9.14%)
  • TFAS 130 -5 (-3.70%)
  • TGRA 102 0 (0.00%)
  • TIFA 210 -8 (-3.67%) © 2010 IMQ - LKBN ANTARA
  • TINS 710 15 (2.16%)
  • TIRA 258 46 (21.70%)
  • TIRT 52 0 (0.00%)
  • TKIM 8,050 350 (4.55%)
  • TLKM 3,620 0 (0.00%)
  • TMAS 86 0 (0.00%)
  • TMPO 150 5 (3.45%)
  • TNCA 246 0 (0.00%)
  • TOPS 50 -17 (-25.37%)
  • TOTL 410 2 (0.49%)
  • TOTO 254 4 (1.60%)
  • TOWR 875 0 (0.00%)
  • TPIA 9,075 100 (1.11%)
  • TRIN 236 -2 (-0.84%)
  • TRIN-W 25 0 (0.00%)
  • TRIS 300 4 (1.35%)
  • TRUK 84 -2 (-2.33%)
  • TRUS 324 -2 (-0.61%)
  • TSPC 1,370 25 (1.86%)
  • TUGU 3,450 0 (0.00%)
  • UCID 1,600 0 (0.00%)
  • ULTJ 1,650 10 (0.61%)
  • UNIT 177 -1 (-0.56%)
  • UNSP 91 0 (0.00%)
  • UNTR 18,475 125 (0.68%) © 2010 IMQ - LKBN ANTARA
  • UNVR 7,475 75 (1.01%)
  • URBN 1,990 0 (0.00%)
  • URBN-W 29 -1 (-3.33%)
  • VICO 113 3 (2.73%)
  • VINS 108 -2 (-1.82%)
  • VINS-W 8 0 (0.00%)
  • VIVA 50 0 (0.00%)
  • VOKS 306 0 (0.00%)
  • WAPO 88 -8 (-8.33%)
  • WEGE 288 -4 (-1.37%)
  • WEHA 151 0 (0.00%)
  • WICO 496 28 (5.98%)
  • WIIM 138 -1 (-0.72%)
  • WIKA 2,080 30 (1.46%)
  • WOMF 272 22 (8.80%)
  • WOOD 474 4 (0.85%)
  • WOWS 103 1 (0.98%)
  • WSBP 238 0 (0.00%)
  • WSKT 1,220 25 (2.09%)
  • WTON 400 2 (0.50%)
  • XAFA 1,047 2 (0.19%)
  • XBES 964 0 (0.00%)
  • XCID 79 0 (0.00%)
  • XIHD 478 -2 (-0.42%)
  • XIIF 612 7 (1.16%) © 2010 IMQ - LKBN ANTARA
  • XIIT 543 0 (0.00%)
  • XIJI 639 14 (2.24%)
  • XKIV 457 2 (0.44%)
  • XPDV 465 9 (1.97%)
  • XPLQ 475 -33 (-6.50%)
  • XPMI 943 3 (0.32%)
  • XSBC 108 2 (1.89%)
  • XSRI 193 2 (1.05%)
  • YELO 52 1 (1.96%)
  • YELO-W 15 0 (0.00%)
  • YPAS 298 -84 (-21.99%)
  • YULE 200 0 (0.00%)
  • ZBRA 51 -1 (-1.92%)
  • ZINC 356 -4 (-1.11%)
  • ZONE 488 -2 (-0.41%)
Aptorum Group announces further positive data for its ALS-4 small molecule Anti-virulence (Non-bactericidal) drug candidate for the treatment of infections caused by Staphylococcus aureus and on track targeted for IND submission in H2 2020
Published: 10 Feb 2020 20:35 WIB


IMQ, Jakarta —  NEW YORK--(Antara/BUSINESS WIRE)-- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”), including methicillin-resistant Staphylococcus aureus (MRSA, one of the “super-bugs”), based on a novel anti-virulence non-bactericidal approach. Subject to completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in second half of 2020 and commence a phase 1 trial in North America.

ALS-4 is a small molecule which inhibits dehydrosqualene desaturase of S. aureus (incl. MRSA), an enzyme that is critically involved in the biosynthesis of staphyloxanthin, a commonly visible “golden pigment” covering the bacteria. Staphyloxanthin is believed to be primarily responsible for the bacteria’s defense mechanism against the attack from reactive oxygen species (ROS) deployed by phagocytic cells and neutrophils.1

Through inhibiting the production of staphyloxanthin, we believe that ALS-4 renders S. aureus highly susceptible to the host’s immune defense (see below for in vivo data and experimental outline). This novel mechanism is significantly different from the bactericidal approach found in currently marketed antibiotics used to treat S. aureus, which are experiencing increasing drug resistance issues2. Specifically, MRSA infections in humans typically exhibit high rates of morbidity and mortality and can cause metastatic or complicated infections such as infective endocarditis or sepsis, with relapse and hospital readmission after S. aureus bacteremia common and costly3.

Based on our testing in a rat bacteremia survival model, a lethal (109 CFU) dose of MRSA (USA300-LAC) was introduced through the tail vein. ALS-4 was administered orally at 10mg/kg per animal 30 minutes after the infection for twice a day thereafter (N=9). A control untreated group was given a sterile vehicle solution (N=9). Survival was monitored for 7 days. 0 out of 9 animals (0%) in the control untreated group survived past day 4, in contrast, 5 out of 9 animals (56%) treated with ALS-4 survived past day 7, which is determined to be statistically significant compared with the control group (p=0.013).

In addition we conducted a study in a non-lethal rat bacteremia infection model. The animals were challenged with a non-lethal (107 CFU) dose of MRSA (USA300-LAC) through the tail vein. In order to simulate a more realistic clinical scenario, treatment was introduced 14-days after the model induction, where ALS-4 was administered orally twice a day at 10mg/kg per animal (N=8). A control untreated group was given a sterile vehicle solution (N=8). After 7 days of ALS-4 treatment, the kidneys were collected and the bacterial titers were measured. Remarkably, ALS-4 reduced the organ bacterial load by 99.5%, from 63,096±18 CFU/g in the control group to 316±49 CFU/g in the ALS-4 treated group, which is determined to be statistically significant (p=0.01).

Last but not least, ALS-4 has successfully inhibited staphyloxanthin production in 11 strains of S. aureus. These include 5 strains of Methicillin-sensitive S. aureus (MSSA): SH1000, HG003, USA300-JE2, Newman, and ATCC29213 with an IC50 of 70.5±6nM, 54.4±4nM, 37.7±4nM, 23.7±1nM, and 30.02±5nM respectively; 5 strains of Methicillin-resistant S. aureus (MRSA): USA300, USA300-3, USA300-LAC, ST239III, and COL, with an IC50 of 30.8±5nM, 42.8±6nM, 43.6±5nM, 16.3±8nM, and 0.9±1nM respectively; and 1 strain of vancomycin-intermediate S. aureus (VISA), Mu3 with an IC50 of 2.6±1nM.

Based on our testing, we believe ALS-4 increases the susceptibility of S. aureus including MRSA to oxidative damage by inhibiting production of staphyloxanthin,. In a hydrogen peroxide killing assay, after the addition of 1.5% H2O2, ALS-4 demonstrated an additional reduction of bacterial CFU by 93.5%, from 61,600±6437 CFU/ml in the untreated group to 4,000±230 CFU/ml in the ALS-4 treated group, which is determined to be statistically significant (p=0.003).

With respect to the study carried out to investigate the capability of ALS-4 to induce antibiotic resistance in S. aureus after prolonged exposure, USA300-LAC was cultured in 3 different conditions for 10 days. For the treatment group 1 µM of ALS-4 was added; for the positive control group 0.12 µg/mL of clindamycin and 16 µg/mL of erythromycin was added from day 1 to day 4, after which clindamycin was withdrawn. For the negative control group, dimethyl sulfoxide (DMSO) was added. On day 11, the bacteria were harvested and then cultured for 16 hr for the determination of the MIC of clindamycin. The prolonged exposure to ALS-4 or DMSO does not affect the MIC value of clindamycin (0.12 µg/mL); while the prolonged exposure to clindamycin + erythromycin triggers antibiotics resistance rapidly with the MIC increased from 0.12 µg/mL to greater than 5 µg/mL.

Based on our study we believe ALS-4 is unlikely to be prone to drug resistance since it is non-bactericidal. Growth inhibition studies were performed on different strains of S. aureus and other bacteria, including 3 strains of MSSA (ATCC29212, SH1000 and HG003), 1 strain of MRSA (USA300), 1 strain of VISA (ATCC700698 Mu3), as well as 6 different bacteria (E. coli, A. baumannii, S. cerevisiae, B. subtilis, E. faecalis, and K. pneumoniae). In all of the tested strains of bacteria, no growth inhibition effect was observed at the highest tested concentration of ALS-4 (250uM). Therefore ALS-4 does not appear to have any direct bacteriostatic or bactericidal activity against many species of bacteria, thus greatly reducing the selection pressure for drug resistance to emerge.

We also assessed the potential impact on the efficacy of vancomycin, the mainstay of treatment for infections caused by MRSA, when used in conjunction with ALS-4. 8 different strains of S. aureus (USA300 FPR3757, USA300-3, USA300-LAC, USA300-JE2, Mu3, HG003, ATCC29213 and clinical isolate ST239III) were used in this study. Our data showed that no effect on the MIC of vancomycin was observed when the concentration of ALS-4 was below 25 μM. Therefore, we believe that ALS-4 does not interfere with the action of vancomycin.

In addition, compared with the current mainstay of treatment for S. aureus infections such as vancomycin or daptomycin which is typically administered in an IV injectable form (with the exception of an oral form vancomycin specifically for treatment of Clostridium difficile diarrhea and staphylococcal enterocolitis only), an oral active agent enables wider market penetration targeting both outpatient as well as potential prophylactic markets.

GLP Toxicity Data

ALS-4 is currently undergoing IND-enabling studies and has so far shown positive safety profiles. As elucidated in our previous press release dated September 9, 2019, ALS-4 did not show any mutagenicity in the in vitro Ames tests. Our currently generated in vitro micronucleus test results also showed that ALS-4 is not genotoxic, indicating the non-mutagenic nature of the drug. Furthermore, the results of the in vitro hERG assay study predicts a low risk of ALS-4 causing cardiac QT prolongation.

For further general presentation, please visit: http://ir.aptorumgroup.com/static-files/bcf77574-7bd6-4b9d-8110-d53837238f16

For further technical presentation, please visit: http://ir.aptorumgroup.com/static-files/66346f79-7a03-474a-89be-0eaafaa00d9d

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases and other disease areas.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

1 mBio 2017 8(5): e01224-17
2 Microbiol Spectr. 2019 Mar;7(2)
3 Clin Infect Dis. 2019 Nov 27;69(12):2112-2118

Contacts

Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com

Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com

Source: Aptorum Group Limited
Author: Business Wire
-
POPULAR NEWS